DNTH — Dianthus Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $697.13m
- $421.89m
- $6.24m
- 34
- 14
- 69
- 32
Annual income statement for Dianthus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 2.83 | 6.24 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 78.7 | 74.7 | 80.9 | 51 | 108 |
| Operating Profit | -78.7 | -74.7 | -80.9 | -48.2 | -102 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -74.9 | -71.1 | -76.5 | -43.6 | -85 |
| Net Income After Taxes | -74.9 | -71.1 | -76.5 | -43.6 | -85 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -74.9 | -71.1 | -76.5 | -43.6 | -85 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -74.9 | -71.1 | -76.5 | -43.6 | -85 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -27.3 | -20.7 | -20.6 | -8.45 | -2.55 |